SCHEMBL5111527

SCHEMBL5111527

Nc1c[nH]nc1-c1nc2c(=O)n(Cc3ccccc3)ncc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
ALDH1A1 P00352 4/20 0.39
HTT P42858 3/20 0.39
HSD17B10 Q99714 2/20 0.39
NPBWR1 P48145 1/20 0.37
TSHR P16473 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
LMNA P02545 2/20 0.35
HPGD P15428 2/20 0.35
PPARG P37231 2/20 0.35
NCOA2 Q15596 2/20 0.35
NCOA1 Q15788 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NR2E3 Q9Y5X4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5106177 0.77 FGFR1 (0.34)
SCHEMBL8273298 0.74 HSD17B10 (0.51) MAPTALDH1A1HTTHSD17B10NPBWR1
SCHEMBL1645967 0.66 SMN1; SMN2 (0.57) MAPTALDH1A1HSD17B10HPGDNPSR1
SCHEMBL6283876 0.65 NT5E (0.35) MAPTALDH1A1HSD17B10LMNAHPGD
SCHEMBL30061961 0.64 MGAM (0.51) GAAADORA2AADORA1
SCHEMBL28504618 0.64 MGAM (0.51) GAAADORA2AADORA1
SCHEMBL13911130 0.63 ALDH1A1 (0.42) MAPTALDH1A1HTTHSD17B10TSHR
SCHEMBL22989952 0.62 MAPT (0.71) MAPTALDH1A1HTTHSD17B10NPBWR1
SCHEMBL5863967 0.62 TDP1 (0.56) MAPTALDH1A1HTTHSD17B10TSHR
SCHEMBL30061039 0.61 SYK (0.39) MAPTALDH1A1HSD17B10HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors ASTEX THERAPEUTICS LIMITED (UK) 2008-01-03 US disclosed
EP-1781653-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP disclosed
WO-2006003440-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors CDK3, CDK1, GSK3B MAPT 1805/4885ALDH1A1 4017/4885HTT 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.